Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)-Reference-Cited by-同舟云学术

Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review)

Published:2022-09-26 Issue:5 Volume:24 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Sun Ruizhu¹,Hou Zhansheng¹,Zhang Yankui¹,Jiang Bo¹

Affiliation:

1. Department of Medical Care, The Third Affiliated Hospital of Kunming Medical University, College of Clinical Oncology, Kunming Medical University, Kunming, Yunnan 650500, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference227 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Cancer burden of major cancers in China: A need for sustainable actions;Cao;Cancer Commun (Lond),2020

3. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC;Camidge;Nat Rev Clin Oncol,2019

4. Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: Individual patient data meta-analysis of overall survival;Lee;J Natl Cancer Inst,2017

5. Understanding and targeting resistance mechanisms in NSCLC;Rotow;Nat Rev Cancer,2017

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Silencing Nrf2 in cisplatin resistant non-small cell lung cancer cells augments sensitivity towards EGFR inhibitor;Toxicology in Vitro;2024-12

2. Reprogramming hematopoietic stem cell metabolism in lung cancer: glycolysis, oxidative phosphorylation, and the role of 2-DG;Biology Direct;2024-08-24

3. A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma;Molecular Cancer;2024-08-09

4. Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs);Drug Metabolism Reviews;2024-08-09

5. Belamcanda chinensis extract inhibits non-small cell lung cancer proliferation and induces apoptosis via inhibiting the MAPK (Ras/Raf) and Akt pathways;Heliyon;2024-08